Skip to main content

Published

Molnupiravir for treating COVID-19.
Tatz GS. Cochrane Database of Systematic Reviews 2025;10:CD015381.
[In people with mild to moderate COVID‐19 who are not admitted to hospital, molnupiravir probably makes little to no difference in reducing the risk of death compared with placebo or usual care. Molnupiravir may make little to no difference in reducing the need for hospitalisation or helping people get better faster. Molnupiravir probably does not increase the risk of unwanted effects, and does not increase the risk of serious unwanted effects.]
Freely available online

More details
Age Groups
Adults
Conditions and Lifestyle Factors
Coronavirus Infections
Settings
Hospital Ward
Intensive Care
Staff Groups
Medic
Nurse
Nurse Specialist
Pharmacist